Atossa Therapeutics Q3 2026 earnings

ATOS · 2026-11-10 08:15 BMO ET · 8-K on SEC · 10-Q on SEC

Operating expenses declined sequentially and year-over-year, and the company secured a CVR agreement tied to a potential PRV monetization.

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $5.9M (-36.3% YoY)
  • One-offs in the quarter Other income (expense), net $0.1M; Other income (expense), net $0.1M (9M YoY)
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge not stated in the 8-K

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$20.6M$26.1M$41.3M-21.4%
Total assets$26.4M$32.3M$47.6M-18.2%
Total stockholders' equity$21.7M$26.8M$39.4M-19.0%
Weighted average shares outstanding9.99M8.91M8.62M+12.1%

Guidance

MetricGuidePrior guideChange
PRV net proceedsUp to $50M——
PRV share to CVR holders25%——
IND clearanceEarly 2027——
EVANGELINE topline dataQ2 2027——

What drove it

  • Revenue story No revenue reported.
  • EPS story Net loss per share widened year-over-year and sequentially due to higher operating expenses and increased share count.
  • One-off check Other income (expense), net $0.1M (9M YoY) and $0.1M (QoQ)

The good

  • Operating expenses decreased $3.4M YoY
  • CVR agreement for 25% of PRV proceeds (up to $50M)

The bad

  • Net loss per share widened YoY and QoQ
  • Cash balance decreased $5.5M QoQ
  • Weighted average shares outstanding increased 12.1% YoY

The ugly

  • none

Open questions

  • The filing does not state the specific amount of the upfront proceeds from the CVR agreement.
  • The filing does not provide a reconciliation of GAAP net loss to adjusted net loss.
Full release

Atossa Therapeutics (ATOS) earnings release, November 10, 2026

Atossa Therapeutics, Inc. (ATOS) · Form 8-K, Item 2.02 · Filed · SEC filing

Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

SEATTLE, WASHINGTON, November 10, 2026 — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results for the third quarter ended September 30, 2026 and provided an update on recent corporate developments.

“In recent weeks, we took meaningful steps to enable shareholders to participate in potential future value from our rare disease programs,” stated

Steven C. Quay, M.D., Ph.D., Atossa's Chairman, President and Chief Executive Officer.

“Our recently announced contingent value rights agreement entitles holders to share in 25% of the net proceeds, up to $50 million, from the sale of the first priority review voucher awarded to Atossa from its rare disease development programs. At the same time, we continued to advance (Z)-endoxifen toward several near-term milestones, including anticipated FDA clearance of our IND applications in Duchenne Muscular Dystrophy and McCune-Albright Syndrome in early 2027. In December 2026, presentations at the San Antonio Breast Cancer Symposium will include Karisma follow-up results and selected data from the ongoing I-SPY2 study evaluating (Z)-endoxifen in combination with other therapies.”

Third Quarter 2026 & Recent Highlights

• Stapled Contingent Value Rights (CVR) Agreement o

On October 8, 2026, the Company entered into a Stapled Contingent Value Rights Agreement (the CVR Agreement), and the Board of Directors (the Board) declared a dividend of one CVR for each share of Atossa common stock outstanding as of October 19, 2026 and issued thereafter. The CVRs remain attached to the underlying shares and will not trade separately unless the Board elects to detach them. o

CVR holders will be entitled, in the aggregate, to 25% of the net proceeds from the sale or other monetization of the first qualifying U.S. Food and Drug Administration (FDA) priority review voucher (PRV) awarded to Atossa, subject to a maximum aggregate payment of $50 million. o

No PRV has been awarded to the Company, and there can be no assurance that Atossa will receive or monetize a PRV or that any payment will ultimately be made under the CVR Agreement.

• CFO Attendance at Global Genes RARE Drug Development Symposium o

Mark Daniel, Atossa’s Chief Financial Officer, attended the Global Genes RARE Drug Development Symposium, held September 9–11, 2026, in Boston, Massachusetts. The symposium brought together patient advocates, researchers and biopharmaceutical industry leaders to explore research strategies, clinical trial readiness and collaboration in rare disease drug development. Atossa’s attendance supported its efforts to understand patient community priorities and explore approaches to advancing its rare disease development programs.

• CEO Attendance at NORD Rare Diseases and Orphan Products Breakthrough Summit o

Steven C. Quay, M.D., Ph.D., Atossa’s Chairman, President and Chief Executive Officer, attended the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit, held October 25–27, 2026, in Washington, D.C. The Summit brought together patient advocates, researchers, industry leaders and policymakers to discuss advances in rare disease research, drug development, patient engagement and access to treatments. Atossa’s attendance supported its continued engagement with the rare disease community as the Company advances its (Z)-endoxifen programs in Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS).

Anticipated Milestones o

The Company anticipates Investigational New Drug (IND) application clearance from the FDA for (Z)-endoxifen in MAS and DMD by early 2027, with initiation of Phase 2 clinical trials expected in 2027. o

The Karisma trial was completed and the results finalized in the clinical study report. The Company is presenting these data at the San Antonio Breast Cancer Symposium (SABCS) in December 2026, and will publicize the findings thereafter. o

The Company anticipates topline data from the Phase 2 EVANGELINE study of (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal women with ER+/HER2- breast cancer in the second quarter of 2027. Enrollment for the study was completed during the second quarter of 2026. o

Enrollment in the (Z)-endoxifen plus elagolix and (Z)-endoxifen plus abemaciclib arms of the Phase 2 I-SPY2 study is complete, and select data will be presented at SABCS in December 2026.

Financial Results for the Third Quarter Ended September 30, 2026

Operating Expenses.

Total operating expenses were $5.9 million and $24.5 million for the three and nine months ended September 30, 2026, respectively, which represented a decrease of $3.4 million and $1.2 million from total operating expenses for the three and nine months ended September 30, 2025, which were $9.3 million and $25.7 million, respectively. Factors contributing to the changes in operating expenses during the three and nine months ended September 30, 2026, are explained below.

Research & Development (R&D) Expenses.

The following table provides a breakdown of major categories within R&D expenses for the three and nine months ended September 30, 2026 and 2025, together with the dollar change and percentage change in those categories (dollars in thousands):

As (Z)-endoxifen is our only product candidate for which we currently incur R&D expenses, we have not further disaggregated R&D expenses by product candidate.

• ... (truncated)or which enrollment was largely completed during the first nine months of 2026.

• The increase in R&D compensation expense of $0.2 million for the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025, was due primarily to increases in non-cash stock-based compensation expense.

• The decrease in R&D professional fees and other of $0.2 million and $0.7 million for the three and nine months ended September 30, 2026, respectively, compared to the three and nine months ended September 30, 2025, was due primarily to lower regulatory consulting fees related to our (Z)-endoxifen programs during the current year periods.

General and Administrative (G&A) Expenses.

The following table provides a breakdown of major categories within G&A expenses for the three and nine months ended September 30, 2026 and 2025, together with the dollar change and percentage change in those categories (dollars in thousands):

• The decrease in G&A compensation expenses of $0.3 million and $0.8 million for the three and nine months ended September 30, 2026, respectively, compared to the three and nine months ended September 30, 2025, was due primarily to a decrease in headcount in the current year periods compared to the same periods in the prior year.

• The decrease in G&A professional fees and other of $1.0 million for the three months ended September 30, 2026, compared to the three months ended September 30, 2025, was due primarily to a decrease in legal fees of $0.8 million related to the resolution of patent litigation matters during the first half of 2026. The increase in G&A professional fees and other of $1.5 million for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025, was due primarily to higher spend on patent litigation matters during the first half of 2026, which have now been settled, and to a lesser extent, higher legal fees associated with management of our intellectual property portfolio and general legal costs related to SEC compliance and other stock administration matters incurred during the current year period.

Interest Income.

Interest income was $0.2 million and $0.7 million for the three and nine months ended September 30, 2026, respectively, and decreased $0.4 million and $1.2 million compared to the three and nine months ended September 30, 2025, respectively. The decrease was due primarily to lower average cash balances invested in our money market account during the current year periods relative to the same periods in the prior year.

About Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company’s lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings.

(Z)-Endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company’s proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa’s (Z)-endoxifen is not approved for any indication.

Atossa has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for (Z)-endoxifen for the treatment of DMD, as well as Rare Pediatric Disease (RPD) designation for (Z)-endoxifen for the treatment of both DMD and MAS. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a Priority Review Voucher (PRV), which can be used to obtain priority review for a future application or may be sold or transferred to another sponsor. In the last 18–24 months, disclosed PRV sales have ranged from $100–$220 million.

Atossa’s (Z)-endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide.

More information is available at https://atossatherapeutics.com.

Financial statements

Income Statement

For the Three Months Ended September 30, — (Unaudited)

For the Three Months Ended September 30, – 2026For the Three Months Ended September 30, – 2025For the Nine Months Ended September 30, – 2026For the Nine Months Ended September 30, – 2025
Operating expenses
Research and development3,3785,37013,05415,029
General and administrative2,5213,88111,40910,676
Total operating expenses5,8999,25124,46325,705
Operating loss-5,899-9,251-24,463-25,705
Interest income2095707451,935
Other income (expense), net52-11-63
Loss before income taxes-5,638-8,692-23,718-23,833
Net loss-5,638-8,692-23,718-23,833
Net loss per share of common stock - basic and diluted-0.56-1.01-2.58-2.76
Weighted average shares outstanding used to compute net loss per share - basic and diluted9,990,2268,622,2899,178,6868,622,289

Balance Sheet

September 30, 2026 — (Unaudited)

September 30, 2026December 31, 2025
Current assets
Cash and cash equivalents20,57441,299
Restricted cash110110
Prepaid materials3,0143,081
Prepaid expenses and other current assets1,4831,128
Total current assets25,18145,618
Other assets1,2671,990
Total assets26,44847,608
Current liabilities
Accounts payable1,5014,293
Accrued expenses1,2961,307
Payroll liabilities1,1671,558
Other current liabilities7451,097
Total current liabilities4,7098,255
Total liabilities4,7098,255
Stockholders' equity
Common stock - $0.18 par value; 350,000,000 shares authorized; 9,979,298 and 8,611,361 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively1,7961,550
Additional paid-in capital291,698285,840
Treasury stock, at cost; 88,003 shares of common stock at September 30, 2026 and December 31, 2025-1,475-1,475
Accumulated deficit-270,280-246,562
Total stockholders' equity21,73939,353
Total liabilities and stockholders' equity26,44847,608

Cash Flow

From the 10-Q · For the Nine Months Ended September 30, — (Unaudited) (in thousands)

For the Nine Months Ended September 30, – 2026For the Nine Months Ended September 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss-23,718-23,833
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation2,0842,143
Depreciation1212
Changes in operating assets and liabilities:
Prepaid materials67-1,045
Prepaid expenses and other current assets-355585
Other assets711-339
Accounts payable-2,7922,853
Accrued expenses-111,070
Payroll liabilities-391-737
Other current liabilities-35268
Net cash used in operating activities-24,745-19,223
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment-16
Net cash used in investing activities-16
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and warrants4,500
Offering costs for common stock and warrant issuance-501
Proceeds from issuance of common stock under the ATM program, net of issuance costs21
Net cash provided by financing activities4,020
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH-20,725-19,239
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE41,40971,194
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE20,68451,955
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents20,57451,845
Restricted cash110110
Total cash, cash equivalents and restricted cash20,68451,955

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of applicable securities laws, including but not limited to, our full year 2026 outlook; our expectations regarding the Company’s development and regulatory strategy and related milestones, including the timing of data; the potential indications that the Company may pursue for (Z)-endoxifen; the potential role of (Z)-endoxifen and (Z)-endoxifen-related compounds in endocrine therapies; the potential for (Z)-endoxifen to receive regulatory approval to commence clinical trials for DMD and MAS and the timing thereof; the Company's progress across its pipeline and potential commercialization; the strength of the Company's patent portfolio; the Company’s potential eligibility for, the value of, and the Company's ability to monetize a Rare Pediatric Disease PRV; potential payments under the CVR Agreement; and the potential market and growth opportunities for the Company. Words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “design,” “predict,” “future,” or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.... (truncated)ing, completion and results of our preclinical studies, clinical trials, and research and development programs; the potential clinical significance of preclinical data and the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to receive orphan-drug exclusivity for (Z)-endoxifen for MAS; our ability to receive a PRV from the FDA; changes to, or the expiration of, the Rare Pediatric Disease PRV program; our ability to monetize any PRV we may receive and our expectations around any PRV’s potential future value; the number of outstanding CVRs, our ability to make a payment to CVR holders, and the expected timing of such payment, if any; our ability to maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa’s filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

The market value of a PRV is variable and subject to a number of factors beyond our control and reported past PRV sale amounts are not necessarily indicative of PRV sale amounts in the future.

Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.

Investor and Media Contacts

Investors: WaterSeid Partners, Inc. — ATOS@waterseid.com

Media: Elev8 New Media — atossa@elev8newmedia.com

ATOSSA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED B

ALANCE SHEETS

(amounts in thousands, except share and per share data)

(Unaudited)

ATOSSA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STAT

EMENTS OF OPERATIONS

(amounts in thousands, except share and per share data)

(Unaudited)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.